ATE183085T1 - Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten - Google Patents

Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten

Info

Publication number
ATE183085T1
ATE183085T1 AT94112616T AT94112616T ATE183085T1 AT E183085 T1 ATE183085 T1 AT E183085T1 AT 94112616 T AT94112616 T AT 94112616T AT 94112616 T AT94112616 T AT 94112616T AT E183085 T1 ATE183085 T1 AT E183085T1
Authority
AT
Austria
Prior art keywords
antagonist
eye
regulation
treatment
blocking
Prior art date
Application number
AT94112616T
Other languages
English (en)
Inventor
Alan M Laties
Richard A Stone
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/522,241 external-priority patent/US5122522A/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE183085T1 publication Critical patent/ATE183085T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT94112616T 1989-06-21 1990-06-14 Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten ATE183085T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36929389A 1989-06-21 1989-06-21
US07/522,241 US5122522A (en) 1989-06-21 1990-05-11 Treatment and control of ocular development

Publications (1)

Publication Number Publication Date
ATE183085T1 true ATE183085T1 (de) 1999-08-15

Family

ID=27004525

Family Applications (3)

Application Number Title Priority Date Filing Date
AT94112616T ATE183085T1 (de) 1989-06-21 1990-06-14 Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
AT96108497T ATE203666T1 (de) 1989-06-21 1990-06-14 Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
AT90911118T ATE147626T1 (de) 1989-06-21 1990-06-14 Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT96108497T ATE203666T1 (de) 1989-06-21 1990-06-14 Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
AT90911118T ATE147626T1 (de) 1989-06-21 1990-06-14 Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung

Country Status (10)

Country Link
US (2) US5356892A (de)
EP (1) EP0478694B1 (de)
JP (4) JP3165436B2 (de)
AT (3) ATE183085T1 (de)
CA (1) CA2058768C (de)
DE (3) DE69029734T2 (de)
DK (1) DK0737475T3 (de)
ES (2) ES2159661T3 (de)
HK (1) HK1007681A1 (de)
WO (1) WO1990015604A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
ATE183085T1 (de) * 1989-06-21 1999-08-15 Univ Pennsylvania Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
WO1993013777A1 (en) * 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
CA2276287C (en) * 1997-01-06 2007-10-30 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
KR20020081260A (ko) * 2000-01-18 2002-10-26 밸리 포지 파마슈티컬즈, 인크. 안구 성장 및 니코틴 길항제
JP2004531569A (ja) * 2001-05-25 2004-10-14 ヴァリー フォージ ファーマスーティカルズ、インコーポレイテッド ピレンゼピン眼科用ゲル剤
ITUB20160876A1 (it) 2016-02-19 2017-08-19 Dambrosio Enzo Maria Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
ATE183085T1 (de) * 1989-06-21 1999-08-15 Univ Pennsylvania Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
ES2159661T3 (es) 2001-10-16
JPH05500502A (ja) 1993-02-04
DK0737475T3 (da) 2001-10-08
US5637604A (en) 1997-06-10
WO1990015604A1 (en) 1990-12-27
CA2058768A1 (en) 1990-12-22
EP0478694A1 (de) 1992-04-08
EP0478694A4 (en) 1992-07-29
DE69033775D1 (de) 2001-09-06
DE69029734D1 (de) 1997-02-27
ES2136686T3 (es) 1999-12-01
JP3165436B2 (ja) 2001-05-14
DE69033775T2 (de) 2001-11-15
ATE203666T1 (de) 2001-08-15
JP2000204049A (ja) 2000-07-25
US5356892A (en) 1994-10-18
ATE147626T1 (de) 1997-02-15
DE69033246T2 (de) 1999-12-02
JP2001081046A (ja) 2001-03-27
CA2058768C (en) 2004-08-03
DE69029734T2 (de) 1997-05-28
JP2004075695A (ja) 2004-03-11
DE69033246D1 (de) 1999-09-16
EP0478694B1 (de) 1997-01-15
HK1007681A1 (en) 1999-04-23
JP3461778B2 (ja) 2003-10-27

Similar Documents

Publication Publication Date Title
Hensler et al. A quantitative autoradiographic study of serotonin1A receptor regulation: Effect of 5, 7-dihydroxytryptamine and antidepressant treatments.
DE69911620T2 (de) Muskarinische antagonisten zur behandlung von presbyopie
Neufeld Experimental studies on the mechanism of action of timolol
ATE183085T1 (de) Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
EP0348360A3 (de) Verwendung von Uridin zur Behandlung nervöser Störungen
Trope et al. Beta adrenergic receptors in pigmented ciliary processes.
KR920702622A (ko) 안구 발육의 치료 및 조절
DE68918099D1 (de) Pharmazeutische behandlung einer augenentwicklung.
EP1110554A4 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
JPH08511024A (ja) 眼内圧を低下させる方法および組成物
Anderson et al. Brain 5-hydroxytryptamine and anticonvulsant activity
Stevens et al. Are the pre-and postsynaptic α-adrenoceptors in human vascular smooth muscle atypical?
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
Joy et al. Dose-dependent proconvulsant and anticonvulsant actions of the alpha2 adrenergic agonist, xylazine, on kindled seizures in the rat
CA2369054A1 (en) Treatment and control of ocular development
Hurwitz et al. The effects of the sympathetic nervous system on accommodation: II. Alpha sympathetic nervous system
Damase-Michel et al. Effects of dopaminergic drugs on the sympathoadrenal system
Yonezawa et al. α2-Adrenoceptor antagonists: effects on ejaculation, penile erection and pelvic thrusting behavior in dogs
Elena et al. Characterization of β adrenergic receptors in bovine pigmented ciliary processes
JPS5572193A (en) 9*100dihydroo4hhbenzo*4*5*cycloheptaa *1*22b*thiophenee4*99imine
Rengo et al. Studies on the nature of the vasodilator fibers running in the lumbar sympathetic chain of the dog
TODOROV et al. Possible role of the α1-adrenoceptor in the modulation of adrenergic co-transmission in the guinea-pig vas deferens
Szalay et al. Effect of beta adrenergic agents on blood vessels of the rat iris I. Permeability to carbon particles
SCHMIDT An accessory adrenal cortex in the kidney of a rhesus monkey and the effects of pyrimethamine on this tissue

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties